1. Signaling Pathways
  2. Neuronal Signaling
  3. CaMK

CaMK

Calmodulin-dependent protein kinases; Calmodulin-dependent kinases

The Ca2+/calmodulin-dependent kinase (CaMK) family has been recognized as a key mediator in living organisms and various biological processes.

CaMK II is a multifunctional cytoplasmic calcium and calmodulin-dependent protein kinase that phosphorylates and alters the function of a variety of substrates. The CaMK II pathway has been found to regulate the RANKL-induced osteoclast formation via the cAMP-response element binding protein (CREB) pathway.

Among many signaling pathways of proliferation, intracellular calciumol/L has been extensively demonstrated to be very important. In cytoplasm, calciumol/L binds to calmodulin, and then activates the CaMKs which are a family of structurally related serine/threonine protein kinases including CaMKI-IV. CaMKII, a multi functional protein kinase, is ubiquitously involved in many physiological processes including control of cell cycle, apoptosis, gene expression, and neurotransmission.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-176149
    Fluoxetine-Conjugated Platinum(IV) prodrug-1
    Inhibitor
    Fluoxetine-Conjugated Platinum(IV) prodrug-1 (Compound 8) is an eEF2K inhibitor. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits cancer cell proliferation, induces DNA damage, cell cycle arrest at S phase and apoptosis. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces ROS accumulation and mitochondrial dysfunction. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits TNBC cell migration and invasion by inhibiting MMP-2 activity. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces autophagy in TNBC cells by activating AMPK. Fluoxetine-Conjugated Platinum(IV) prodrug-1 has antitumor activity and activates immunosuppression in the 4T1-Luc mouse model. Fluoxetine-Conjugated Platinum(IV) prodrug-1 can be used in triple-negative breast cancer (TNBC) research.
    Fluoxetine-Conjugated Platinum(IV) prodrug-1
  • HY-P10638A
    TAT-CN21 (scrambled)
    Control
    TAT-CN21 (scrambled) is a control peptide lacking specific targeting activity, used as a negative control for TatCN21 (HY-P10638). TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII).
    TAT-CN21 (scrambled)
  • HY-162860
    FO-4-15
    Activator
    FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce accumulation, hyperphosphorylated Tau, and synaptic damage.
    FO-4-15
  • HY-RS10438
    PHKA2 Human Pre-designed siRNA Set A

    PHKA2 Human Pre-designed siRNA Set A contains three designed siRNAs for PHKA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    PHKA2 siRNA-1: 5 nmol (HPLC)

    PHKA2 siRNA-2: 5 nmol (HPLC)

    PHKA2 siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)

    PHKA2 Human Pre-designed siRNA Set A
  • HY-111093
    Protein kinase inhibitor 8
    Inhibitor
    Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases.
    Protein kinase inhibitor 8
  • HY-E70813
    CAMKK2 Recombinant Human Active Protein Kinase
    CaMKK2 is a serine/threonine protein kinase and the central component of a Ca2+-calmodulin activated signalling pathway. CaMKK2 is highly enriched in brain neurons and regulates energy metabolism and neuronal processes. CAMKK2 Recombinant Human Active Protein Kinase is obtained by expressing CAMKK2 proteins.
    CAMKK2 Recombinant Human Active Protein Kinase
  • HY-P3943
    Calmodulin Dependent Protein Kinase Substrate Analog
    Calmodulin Dependent Protein Kinase Substrate Analog is a Ca2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases.
    Calmodulin Dependent Protein Kinase Substrate Analog
  • HY-156104
    CaMKIIα-PHOTAC
    Degrader
    CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains.
    CaMKIIα-PHOTAC
  • HY-137658A
    Purine riboside-5'-O-triphosphate sodium
    Inhibitor
    Purine riboside-5'-O-triphosphate sodium, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC50 values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate sodium inhibits calmodulin-dependent protein kinase II (CaMKII) with a Ki value of 590 µM.
    Purine riboside-5'-O-triphosphate sodium
  • HY-RS24288
    Trio Rat Pre-designed siRNA Set A

    Trio Rat Pre-designed siRNA Set A contains three designed siRNAs for Trio gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    Trio siRNA-1: 5 nmol (HPLC)

    Trio siRNA-2: 5 nmol (HPLC)

    Trio siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)

    Trio Rat Pre-designed siRNA Set A
  • HY-A0257A
    Prenylamine lactate
    Inhibitor
    Prenylamine lactate is a calcium-modulating protein (CaM) antagonist that inhibits CaM-dependent enzymes and can slowly relax smooth muscle preparations. The effect of Prenylamine lactate on smooth muscle is not inhibited by the calcium agonist Bay K 8644 (HY-10588). Reports suggest that under low heart rate conditions, Prenylamine seems to enhance voltage-dependent transmembrane calcium currents.
    Prenylamine lactate
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.